• potency testing of biologicals; • interpretation of “ protection” against diseases and “ reduction” of clinical symptoms in the context of efficacy claims for vaccines; • the definition of a new active substance, with regard to biologicals; and • the need for compliance with monographs of the European Pharmacopoeia.